Stay updated on Daratumumab in Waldenström Macroglobulinemia Clinical Trial
Sign up to get notified when there's something new on the Daratumumab in Waldenström Macroglobulinemia Clinical Trial page.

Latest updates to the Daratumumab in Waldenström Macroglobulinemia Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedRevision: v3.3.4 is now displayed, replacing Revision: v3.3.3; this appears to be a maintenance update without changes to study content or outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check16 days agoNo Change Detected
- Check30 days agoChange DetectedThe page now shows a Locations section with sites in Massachusetts, Minnesota, New York, and Washington. The HHS Vulnerability Disclosure link has been removed.SummaryDifference0.6%

- Check59 days agoChange DetectedThe page now displays a new revision label, changing from v3.2.0 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check66 days agoChange DetectedRemoved the banner notice about government funding and operating status; core study details and links remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check81 days agoChange DetectedBoth screenshots display the same study page with identical content; only minor visual/layout differences are present. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check109 days agoChange DetectedSignificant update to the site version (v3.1.0 → v3.2.0) and new government-operation notice; removal of a specific resource entry (Waldenstrom macroglobulinemia).SummaryDifference4%

Stay in the know with updates to Daratumumab in Waldenström Macroglobulinemia Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Daratumumab in Waldenström Macroglobulinemia Clinical Trial page.